Company Description
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity.
It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes.
The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity.
The company was incorporated in 2017 and is headquartered in San Carlos, California.
| Country | United States |
| Founded | 2017 |
| IPO Date | Apr 16, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 41 |
| CEO | Michael J. Hitchcock |
Contact Details
Address: 1599 Industrial Road San Carlos, California 94070 United States | |
| Phone | 650 980 9099 |
| Website | biomeafusion.com |
Stock Details
| Ticker Symbol | BMEA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 1840439 |
| CUSIP Number | 09077A106 |
| ISIN Number | US09077A1060 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael J. M. Hitchcock Ph.D. | Interim Chief Executive Officer and Director |
| Ramses M. Erdtmann | Co-Founder, President, Chief Operating Officer and Director |
| Heow Tan | Chief Technology and Quality Officer |
| Dr. Thorsten Kirschberg Ph.D. | Executive Vice President of Research |
| Dr. Stephan Morris M.D. | Chief Development Officer |
| Ravi Upasani Ph.D. | Executive Vice President of Intellectual Property |
| Caroline Perez- Dupont J.D. | Senior Vice President of Contracts |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 11, 2026 | 10-Q | Quarterly Report |
| May 11, 2026 | 8-K | Current Report |
| Apr 28, 2026 | 8-K | Current Report |
| Apr 27, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 27, 2026 | ARS | Filing |
| Mar 24, 2026 | 10-K | Annual Report |
| Mar 24, 2026 | 8-K | Current Report |
| Feb 25, 2026 | 8-K | Current Report |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 12, 2026 | SCHEDULE 13G | Filing |